Boston Scientific's most recent trend suggests a bullish bias. One trading opportunity on Boston Scientific is a Bull Put Spread using a strike $34.00 short put and a strike $29.00 long put offers a potential 18.2% return on risk over the next 10 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $34.00 by expiration. The full premium credit of $0.77 would be kept by the premium seller. The risk of $4.23 would be incurred if the stock dropped below the $29.00 long put strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Boston Scientific is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Boston Scientific is bearish.
The RSI indicator is at 39.44 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Boston Scientific
Boston Scientific Announces Conference Call Discussing Fourth Quarter 2018 Financial Results And Investor Update At NANS 2019
Fri, 04 Jan 2019 15:30:00 +0000
MARLBOROUGH, Mass. , Jan. 4, 2019 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the fourth quarter …
GE’s Healthcare Unit Spin-Off to Enhance Shareholder Wealth
Fri, 04 Jan 2019 12:31:40 +0000
Will Restructuring Initiatives Put GE Back on Growth Trajectory? As part of its June 2018 major restructuring plan, General Electric (GE) intends to spin off the Healthcare segment and turn it into a standalone entity. The move is believed to be another step by newly appointed CEO Larry Culp to optimize the company’s business and strengthen its liquidity position.
New Study Raises Concerns About Overuse of Stents
Mon, 31 Dec 2018 17:00:00 +0000
Stent manufacturers such as Abbott Laboratories and Medtronic still expect demand for stents to remain steady.
Boston Scientific (BSX) to Buy Residual Shares of Millipede
Mon, 31 Dec 2018 13:28:01 +0000
Boston Scientific's (BSX) buyout of the leftover stake in Millipede will integrate the latter's IRIS Transcatheter Annuloplasty Ring System in the Structural Heart portfolio of the former.
Boston Scientific’s latest deal is a good fit, analysts say
Sun, 30 Dec 2018 16:22:00 +0000
Boston Scientific’s latest deal, a takeover of privately held Millipede, will help the company build out its franchise of heart-valve repair and replacement treatments, Needham analysts said Thursday.
Also on Market Tamer…
Follow Us on Facebook